US20050100970A1 - Method of affinity separation and ligands for use therein - Google Patents
Method of affinity separation and ligands for use therein Download PDFInfo
- Publication number
- US20050100970A1 US20050100970A1 US11/000,747 US74704A US2005100970A1 US 20050100970 A1 US20050100970 A1 US 20050100970A1 US 74704 A US74704 A US 74704A US 2005100970 A1 US2005100970 A1 US 2005100970A1
- Authority
- US
- United States
- Prior art keywords
- protein
- derivative
- domain
- affinity
- asn residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 239000003446 ligand Substances 0.000 title claims abstract description 49
- 238000000926 separation method Methods 0.000 title claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 156
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 147
- 235000018102 proteins Nutrition 0.000 claims abstract description 138
- 238000009739 binding Methods 0.000 claims abstract description 53
- 230000027455 binding Effects 0.000 claims abstract description 49
- 230000004048 modification Effects 0.000 claims abstract description 12
- 238000012986 modification Methods 0.000 claims abstract description 12
- 235000001014 amino acid Nutrition 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 22
- 108010088160 Staphylococcal Protein A Proteins 0.000 claims description 11
- 108020001507 fusion proteins Proteins 0.000 claims description 11
- 230000009870 specific binding Effects 0.000 claims description 11
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002823 phage display Methods 0.000 claims description 4
- 101710096438 DNA-binding protein Proteins 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 102100027211 Albumin Human genes 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract description 7
- 235000009582 asparagine Nutrition 0.000 abstract description 7
- 229960001230 asparagine Drugs 0.000 abstract description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- 229940024606 amino acid Drugs 0.000 description 33
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 32
- 108091006905 Human Serum Albumin Proteins 0.000 description 25
- 102000008100 Human Serum Albumin Human genes 0.000 description 25
- 238000006467 substitution reaction Methods 0.000 description 14
- 238000002703 mutagenesis Methods 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 231100000350 mutagenesis Toxicity 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 238000001042 affinity chromatography Methods 0.000 description 11
- 239000012491 analyte Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 235000004279 alanine Nutrition 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 230000006240 deamidation Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002708 random mutagenesis Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 230000003019 stabilising effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- -1 cyclic imide Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011012 sanitization Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- PLVPPLCLBIEYEA-WAYWQWQTSA-N (z)-3-(1h-indol-3-yl)prop-2-enoic acid Chemical compound C1=CC=C2C(\C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-WAYWQWQTSA-N 0.000 description 1
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 241000194015 Streptococcus sp. G148 Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003164 beta-aspartyl group Chemical group 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to affinity separation and to ligands for use therein.
- Affinity separations generally take place on an affinity chromatography column and take advantage of the potentially highly specific nature of interactions involving biomolecules, especially proteins.
- Other possible separation methods include membrane filtration, two-phase extraction, fluidised beds, expanded beds and magnetic bead separation (Scopes, R. K. Protein Purification, Principles and Practice, 3rd Ed. ISBN 0-387-94072-3). Interactions include protein-protein, protein-nucleic acid, enzyme-substrate, receptor-ligand (e.g. hormone) protein- carbohydrate and protein-metal interactions.
- affinity separation is based on the biologically important binding interactions that occur on protein surfaces, such as that between an enzyme and its substrate, between nucleic acid and a DNA binding protein or between antigen and antibody.
- Either one of a pair of binding partners can be immobilised, e.g. by covalent bonding to an insoluble matrix in an affinity column in order to assay for or purify its binding partner.
- affinity binding molecules particularly proteins makes them ideal for purification/separation techniques and for many applications, affinity chromatography involving an immobilised protein ligand is preferred over ion-exchange or gel-filtration chromatography.
- a sample is added to a column which carries immobilised on a solid matrix a specific binding partner to a target molecule in the sample, the target molecule will be retained in the column while the majority of the non-target molecules will simply run through.
- a solution typically containing a gradually decreasing pH can be added to the column to wash through firstly any non-specifically bound molecules and finally to elute the target molecule.
- the target molecule having the highest affinity for the immobilised ligand, will be the last molecule to be washed off the column and it is therefore the final fractions which will contain the highest concentration of the target molecule and can then be used in a further purification/concentration step or be assayed directly or indirectly for the presence of the target molecule.
- affinity separation is important in assaying samples quantitatively and qualitatively for a target molecule. This may be important, for example, when blood or urine samples are being assayed for molecules indicative of a disease such as a metabolic disorder or even the presence of non-naturally occurring substances, narcotics, steroid derivatives etc.
- An affinity chromatography column complete with its solid affinity matrix, can be expensive and clearly it is desirable to be able to re-use the column several times, i.e., to complete a number of runs before it has to be discarded due to reduced ability of the immobilised ligand to bind a target molecule or to a reduced specificity of binding.
- the recognised standard for cleaning and sanitizing separation media and systems is NaOH, often in combination with NaCl.
- An applied 0.1-1.0 M NaOH solution is able to remove viruses, bacteria, nucleic acid, proteins, yeasts, endotoxins, prions and other contaminating agents.
- the NaOH contact time may vary, between 30 minutes and 1 hour is typical, and removal from the system is monitored by simple in-line pH and conductivity measurements.
- the ability of the separation media to withstand these rather harsh sanitizing conditions depends on the functional groups of the attached ligand(binding partner), attachment chemistries, and the stability of the base matrices to alkaline conditions. Proteins are sensitive to extreme pH, such as is experienced during NaOH cleaning and, generally speaking, this will adversely affect the effectiveness of protein-based affinity media. Thus, although protein based affinity separation has advantages over ion exchange and gel-filtration chromatography due to its good specificity, these other less specific techniques are not adversely affected by standard cleaning methods.
- the sensitivity of proteins to alkaline pH is primarily due to deamidation of asparagine and glutamine residues, particularly asparagine residues.
- Deamidation of asparagine results in the formation, via a cyclic imide intermediate, of isoaspartate and aspartate, usually in the ratio of 3:1 to 4:1. This reaction does take place at physiological pH but is far faster at alkaline pH such as present in a chromatography column which is being cleaned by an NaOH solution.
- the isoaspartyl form is characterised by an atypical amide bond between the ⁇ -carboxyl of aspartate and the ⁇ -nitrogen of the C-flanking amino acid.
- the present invention provides a method of affinity separation wherein the affinity ligand is an immobilised proteinaceous ligand wherein one or more of its asparagine residues has been modified.
- modified includes deletion of the asparagine residue or replacement of it with a less alkaline-sensitive amino acid, or wherein the asparagine residue has been modified by substitution (i.e. chemical substitution of one or more groups) or other chemical derivitisation, e.g. by a protecting group. Replacement of one or more asparagine residues with a less alkaline-sensitive amino acid is preferred.
- affinity separation any purification or assaying technique which involves the addition of a sample containing a target analyte to a solid which carries on it a specific binding partner to the analyte.
- Gravity or other means allows the sample to pass through or across the solid, and the interaction between the analyte and its specific binding partner immobilised on the solid means that the analyte will be retained on the solid while the rest, or most of the rest, of the sample passes through the system.
- the separation may conveniently be carried out on an affinity chromatography column.
- the solid is preferably arranged in a column, so that the sample can be added to the top and the non-target part of the sample runs off.
- An eluant such as a salt solution or a change of pH can be used to displace the specifically bound analyte which can then be collected in a number of aliquots in a controlled manner.
- an “affinity ligand” is thus a target-specific binding partner, which can be used in an affinity separation process.
- Alyte is used to refer to any molecule or fragment of a molecule, proteinaceous or otherwise, in a sample which is capable of binding specifically to the immobilised ligand.
- binding partner may include a molecule or a group of related molecules and any one of these molecules may also bind ‘specifically’ to one or more other molecules.
- the term does not imply that any one immobilised ligand or analyte can have only one binding partner, rather that binding is specific to the extent that most other molecules will not bind with the same affinity or with the same stringency, particularly that other non-target molecules in a given sample will have a much lower affinity. Purification by affinity separation is often of the order of several thousand-fold because of the high affinity between biologically specific binding partners.
- affinity separation which include an immobilised proteinaceous ligand can be used in the method of the invention, and suitable matrices (i.e. solid support) known for use with particular ligands are known in the art, typically based on chromatography using agarose, polacrylamide, silica, polyvinyl styrene, dextran or other polymers.
- suitable matrices i.e. solid support
- Any of the solid support known in the art for separation or immobilisation processes may be used, as indeed may any of the methods known in the art for attaching molecules such as affinity ligands to solid supports.
- the proteinaceous ligands are usually attached to the matrix by a coupling agent such as cyanogen bromide, epichlorohydrin, bisoxirane, divinyl sulfone, carbonyl diimidazol, N-hydroxysuccinimide, tosyl/tresyl chloride, epichlorohydrine, carbodiimide, glutaraldehyde, hydrazine, oxirane and also carboxyl or thiol activated matrices and again such coupling agents and coupling chemistries are well known in the art and widely described in the literature (Jansson, J. C. and Ryden, L. Protein purification, 2nd Ed. pp 375-442, ISBN 0-471-18626-0).
- Various derivatives of matrices which allow straightforward immobilization include CNBr-activated Sepharose 4B, AH-Sepharose 4B and CH-Sepharose 4B and Epoxy-activated Sepharose 6B (Pharmaci
- the proteinaceous affinity ligand may be a molecule having a protein component, which may function as a “specific binding partner” as defined above.
- a protein component which may function as a “specific binding partner” as defined above.
- glycoproteins or protein-lipid complexes or indeed proteins with prosthetic groups may be used as the affinity ligand which is modified according to the present invention.
- Protein molecules are, however, preferred.
- the term “protein” is used herein broadly to include any molecule having a polypeptide or peptide structure. In other words, as used herein, a “protein“is made up of a chain of amino acids, and the term does not imply any particular conformational (i.e. tertiary structure) or other requirement.
- Suitable amino acids to replace asparagine include any of the other 19 standard naturally occurring amino acids, although cysteine and glutamine would not be preferred.
- Preferred substituting amino acids include lysine, aspartic acid and leucine.
- Non-naturally occurring amino acids and amino acid derivatives which are well known to the man skilled in the art could also be used to replace asparagine residues.
- Significant improvements in the stability of the immobilised protein and thus the efficacy of the column after cleaning can be observed when just one asparagine is substituted by a less alkaline sensitive residue but preferably 2, 3 or more, or even all of the asparagine residues are substituted.
- a “less alkaline-sensitive amino acid” is one which is less susceptible to degradation under alkaline conditions than Asn, when compared using techniques, methods and conditions known in the art. Such conditions may, for example, be the column washing conditions discussed above, or any other alkaline conditions used in the art to study protein stability or degradation e.g. deamidation as discussed above.
- a “less alkaline-sensitive” amino acid may thus be any amino acid other than Asn, and more preferably other also than Gln and Cys.
- alkaline-sensitivity may be compared by replacing a given Asn residue in a protein molecule with a substitute amino acid, or by chemically modifying or derivatising the said Asn residues, and then comparing stability in alkaline conditions (e.g. column wash conditions) with the unmodified protein.
- the sensitivity of a particular asparagine residue to deamidation will depend on the configuration of the protein, it being particularly important to replace those residues which are on the surface of the three dimensional structure of the protein and thus particularly exposed to the alkaline conditions. It is the overall stability of the ligand which is of most importance and it is desirable to retain the specificity of the interaction between the immobilised ligand and its binding partner, therefore, preferably it is the asparagine residues not involved in the ligand-analyte interaction which are replaced.
- the “asparagine modified” proteinaceous affinity ligand may be made by any method known to the skilled man. Standard techniques for site-directed mutagenesis of nucleic acids are described, for example, in the laboratory manual entitled Molecular Cloning by Sambrook, Fritsch and Maniatis. A preferred technique involves PCR mutagenesis, where primers which incorporate the necessary mis-match base pairs to generate the desired mutations are used in a first round of PCR. In the second run, the fragments from the first run are mixed and the polymerase is able to fill in the strands. The resulting double stranded fragment can be ligated into a plasmid which is then used to transform E. coli. The protein can by synthesised in vitro without using a biological host and in this case non-naturally occurring amino acids can be introduced.
- affinity separation As well as the many general uses of affinity separation indicated previously, of particular interest in the present case is the use of affinity separation with ligands which have been made by randomisation (random mutagenesis) of a particular protein to generate ligands with novel, modified or enhanced binding characteristics. These proteins are referred to as combinatorial proteins.
- Such a technique typically involves random mutagenesis of a target protein, expression of the full library of these variants, e.g. on the surface of filamentous bacteriophage, followed by selection of a protein exhibiting the desired binding characteristics, this selection typically involving a binding reaction between the variant protein and an immobilised ligand (binding partner) i.e. target molecule for the protein, e.g. target analyte.
- the mutagenesis is random in that the resulting amino acid encoded by any particular codon is not generally pre-determined but the positions where mutations are to be introduced are generally identified in advance.
- the mutagenesis may involve amino acid substitution deletion, or addition (e.g. insertion).
- an expression system such as surface display on phage provides a crucial link between genotype and phenotype; there is a self-contained unit which can be selected on the basis of its specific binding interactions and which also carries the nucleic acid encoding for the protein responsible for the observed binding characteristics. This enables expression in useful amounts of the protein selected for its binding characteristics, such expression typically taking place in a transformed bacterial host.
- the protein selected by its ability to bind to an immobilised ligand (e.g. a desired target molecule (analyte)), is then itself used in affinity separation (i.e. as the affinity-ligand). It is immobilised and used to purify or assay for a target molecule in a sample, typically the same ligand which was used to select the protein in the first place.
- an immobilised ligand e.g. a desired target molecule (analyte)
- affinity separation i.e. as the affinity-ligand
- the affinity separation methods of the invention provide excellent purification methods, yielding samples of a target molecule having good purity.
- the methods of the invention will still produce pure samples after many cycles of the separation system, e.g. after many runs, with washing, of a column. Such samples produced by the methods of the invention constitute further aspects of the invention.
- a protein is stabilised by replacing one or more of its asparagine residues with a less alkaline sensitive amino acid prior to the randomisation and selection steps described above, then its useful life as an affinity ligand will be extended due to its ability to withstand the harsh conditions such as high pH which are experienced when an affinity column is washed between runs.
- a further aspect of the present invention comprises a combinatorial protein wherein in a step separate from the randomisation step (i.e. the step used to generate the combinatorial protein by randomisation of an “origin” or “source” or “starting protein”), the stability of the protein in alkaline conditions has been increased by modifying one or more of its asparagine residues (preferably by replacing one or more of its asparagine residues with a less alkaline sensitive amino acid).
- Nucleic acid molecules encoding such a protein as well as cells expressing the protein constitute further aspects of the present invention.
- the randomisation may itself result in substitution of asparagine residues but this aspect of the invention is concerned with proteins which have also been specifically modified to replace one or more asparagine residues in order to increase stability.
- the protein can be stabilised before or after the randomisation or at the same time but preferably the stabilising modifications will be introduced before the randomisation takes place. If stabilisation is performed before randomisation, it need only be performed once, and by selecting from the library of randomised variants against a number of ligands, several stabilised proteins with different binding characteristics can be obtained. If the stabilisation is performed after selection for a particular binding affinity, then there is a risk that some affinity would be lost as a result of the stabilising substitutions.
- Suitable protein scaffolds may simply be linear peptides but preferably the scaffold will possess a folded three dimensional structure which has the potential for higher affinities and is less susceptible to proteolytic degradation. Rather than designing a scaffold de novo, naturally existing proteins or domains are usually selected for further engineering. For the avoidance of doubt, it is to be noted that throughout this specification the word “protein” is used to refer to whole protein molecules as well as domains or fragments thereof, polypeptides or peptides.
- the choice of protein scaffold depends on several parameters including an ability to be effectively expressed in a desired host organism e.g E. coli when the randomised protein is to be displayed as a fusion protein with a filamentous.phage coat protein.
- the protein should also comprise sufficiently large regions on its surface which are tolerant to substitution (or insertion or deletion etc.) without losing the overall three dimensional structure. If the library is to be produced synthetically, a small overall size is a prerequisite.
- amino acid residues involved in that interaction may be a target for randomisation. Randomisation may be performed in order to enhance known binding properties or to develop ligands with new specificities.
- Suitable scaffold molecules are discussed in Nygren et al. (1997) and include cyclic peptides having 40 or more residues in a constrained sequence, immunoglobulin-like scaffolds including Fv or single-chain (scFv) domains, bacterial receptors such as the 58-residue one-domain Staphylococcal protein A (SPA) analogue Z (the “Z Domain” being a derivative of the B domain of SPA), or other domains or analogues of SPA, DNA-binding proteins particularly zinc fingers and protease inhibitors. All these molecules can be stabilised by substituting one or more native asparagine residues with a less alkaline sensitive amino acid before a combinatorial library of the pre-stabilised protein is made.
- SPA Staphylococcal protein A
- Z Domain being a derivative of the B domain of SPA
- DNA-binding proteins particularly zinc fingers and protease inhibitors. All these molecules can be stabilised by substituting one or more native asparagine residues
- Selection from a generated protein library can be performed in a number of different ways known in the art, including bead immobilised libraries (McBride, J. D., Freeman, N., Domingo, G. J. and Leatherbarrow, R. J., J. Mol. Biol. [1996] 259: 819-827), fusions to DNA-binding proteins (Schatz, P.J., Biotechnology [1993]11, 1138-1143) and when displayed on bacteria (Lu, Z., Murray, K. S., Van Cleave, V., LaVallie, E. R., Stahl, M. L. and McCoy, J. M. Biotechnology [1995], 13 366-372) or phage (Clackson, T.
- yeast cells (Boder, E.T. and Wittrup, K. D., Nature Biotechnology (1997) 15, 553-557) and in viral systems (Ernst, W., Grabher, R., Wegner, D., Borth, N., Graussauer, A. and Katinger, H. Nucleic Acids Research (1998) 26, 1718-1723 and Grabher, R., Ernst, W., Doblhoff-Dier, O., Sara, M. and Katinger, H. BioTechniques (1997) 22, 730-735).
- the present invention provides a method of preparing a combinatorial library of protein molecules wherein the protein has been rendered less sensitive to alkaline pH by modification of one or more of its asparagine residues before it is randomised (preferably by replacement of one or more of its asparagine residues).
- a method of phage display wherein a protein expressed on the phage surface has had one or more of its asparagine residues modified (preferably by replacement with a less alkaline sensitive residue) in a step separate to any modifications introduced in order to modify binding characteristics of the protein.
- a further aspect of the present invention comprises a method of making a stabilised combinatorial protein comprising the steps of:
- step a) will preferably comprise replacement of asparagine residues with other less alkaline sensitive amino acids, Step a) is preferably carried out before step b).
- the present invention also relates to fusion proteins comprising a stabilised part and a randomised part, such proteins being useful in certain applications.
- this technique enables the development of a stable framework which can have attached thereto a variable region with specific binding characteristics.
- the variable region can be prepared by randomisation techniques as discussed above and a protein molecule having desired binding characteristics can be selected from the library of variants, for example by phage display and affinity chromatography.
- This randomised protein can then be expressed as a fusion protein, e.g. in E. coli, together with a protein molecule which has already been engineered to improve its stability to alkaline conditions by replacing one or more of its asparagine residues with other less alkaline sensitive residues.
- the fusion protein can be used as an immobilised ligand in affinity chromatography, giving the benefits of a generally stable molecule provided by the framework part as well as a pre-selected binding affinity provided by the randomised part.
- Such a system may enable the use of a small protein molecule during the randomisation and selection stage as important protein-like characteristics (as opposed to peptide characteristics) are provided by the stabilised part.
- the same stabilised part can be used together with a variety of different randomised molecules and vice versa.
- Suitable protein molecules to perform as the stabilised framework part of the fusion peptides include Albumin Binding Protein (ABD); the bacterial receptor domain Z is a suitable molecule for randomisation in this context.
- the present invention also provides a fusion protein comprising a first part wherein one or more naturally occurring asparagine residues have been modified (preferably replaced by an amino acid residue less sensitive to high pH) and a second part being a randomised protein molecule selected for its specific binding properties.
- Nucleic acid molecules encoding such a protein as well as cells expressing the protein constitute further aspects of the present invention.
- a further aspect of the present invention comprises a method of stabilising an affinity ligand by modifying one or more of its asparagine residues (preferably the affinity ligand is stabilised by replacing one or more of its asparagine residues with an amino acid residue less sensitive to alkaline pH).
- a still further aspect comprises the use of a protein molecule stabilised by modification of one or more of its asparagine residues in surface display or in affinity chromatography.
- surface display refers to the technique involved in selection of a protein from a library of molecules which are presented (displayed) in a manner which enables differentiation between the protein molecules on the basis of their binding characteristics.
- Surface display is typically performed on the surface of filamentous bacteriophage (phage display) but display can also be on the surface of bacteria, yeast cells or using viral systems. Any “surface display” technique known or proposed in the art, may be used according to the present invention.
- a preferred affinity ligand for use in the methods of the invention is Albumin Binding Protein (ABD), a protein domain with affinity towards human serum albumin (HSA). It is derived from a cell wall anchored bacterial receptor protein from Streptococcus G148. It is of particular use as an affinity ligand for the purification of human serum albumin (HSA).
- the wild type sequence of this protein has four asparagine residues, enhanced stability is observed when just one of these residues is substituted but preferably all four residues are replaced by less alkaline sensitive residues.
- the wild type amino acid sequence of ABD is: LAEAKVLANRELDKYGV-SDYYKNLINNAKTVEGVKALIDEILAALP the asparagine residues have been indicated in bold.
- ABDwt the first asparagine residue of ABDwt which may be stabilised is in position 28 (Asn 28 ).
- Stabilised versions of ABD for use in the methods of the invention may incorporate some, all or none of the 19 amino acid N-terminal tail.
- Stabilised ABD may, as discussed above, be further subjected to randomisation to create a protein (i.e. a combinatorial protein) having e.g. modified binding characteristics for HSA and/or that is able to bind any target of choice and also retains affinity towards HSA.
- the randomisation may involve mutagenesis of the same, or preferably different, residues modified in the stabilisation step.
- Such derivatives of ABD e.g. mutants created by random or directed mutagenesis are also included within the scope of the invention.
- a further aspect of the present invention is Albumin Binding Protein(ABD) or fragments or derivatives thereof wherein one or more native asparagine residue have been replaced by a less alkaline sensitive amino acid.
- Nucleic acid molecules encoding such a protein as well as cells expressing the protein constitute further aspects of the present invention.
- Asn 28 is replaced by leucine, Asn 42 by aspartic acid, Asn 45 by aspartic acid and Asn 46 by lysine (referred to as ABDmut herein).
- ABDmut is used to refer to proteins incorporating some, all or none of the 19 amino acid N-terminal tail.
- Asparagine is the most alkaline sensitive amino acid and so any other amino acid residue could be used to replace it and an increase in stability would be expected. It may be of assistance to compare the sequences of other homologous proteins, which are found in other species or.perform the same role, to identify suitable amino acids to be used in the substitution.
- the modifications were introduced by PCR mutagenesis. Firstly mismatched primers are used to introduce the mutations and then the fragments from the first run of PCR are mixed and the polymerase allowed to fill in the strands. The double stranded fragment of ABD incorporating the modifications is cleaved with restriction enzymes and ligated into a plasmid restricted with the same enzymes, which is then used to transform E. coli, the expression system for the protein.
- the affinity ligand purified (i.e. obtained) according to the methods of the invention retains more than 80%, preferably more than 95%, of its normal binding capacity after 20 rounds of treatment with 0.5M NaOH.
- FIG. 1 is a schematic description of the PCR-mutagenesis step according to the invention.
- FIG. 2 shows the cloning of the gene construct
- FIG. 3 is the amino acid sequence of wild type ABD and a mutated alkaline resistant variant of it, the full sequence of the mutated variant is designated herein as SEQ ID NO. 1;
- FIG. 4 shows an SDS-PAGE (4-20%) under reducing conditions.
- Lanes 1 and 2 show purified ABD and ABDstab respectively.
- the third lane shows a molecular weight marker (from top 94, 67, 43, 40, 20.2 and 14.4 kDa respectively).
- E. coli disintegrate was spiked with HSA (lane 4) and loaded onto the column.
- Lanes 5 , 6 and 7 show the eluted material after 2, 8 and 15 rounds of NaOH treatment.
- Lane 8 shows an HSA reference;
- FIG. 5 shows Sensorgrams from the BIACore showing the binding characteristics of (A)ABDwt and (B)ABDmut before and after treatment with 0.5M NaOH for 24 hours;
- FIG. 6 is a diagram showing the capacity of two affinity matrices, ABDwt and ABDmut respectively, after several rounds of treatment with 0.5M NaOH;
- FIG. 7 shows sensorgrams from the Biacore experiment described in Example 10 showing the binding characteristics of ABDmut and the three different triple-mutants thereof, Response Unit (RU) v Time (S); A ABDmu; ⁇ 29-30-33A; ⁇ 54-57-58 A; ⁇ 22-25-26 A.
- RU Response Unit
- S Time
- pTrpABDT1T2 As a template for the PCR mutagenesis pTrpABDT1T2 was used (Kraulis et al. (1996) FEBS Lett. 378, 190-194).
- the plasmid encodes the gene for ABDwt under control of the tryptophan promoter.
- the PCR mutagenesis was performed in two steps. In the first PCR the mutations was introduced and in the second round of PCR, the fragments from the first run were mixed and the polymerase was allowed to fill in the strands ( FIG. 1 ).
- the primers used in the first PCR were: 5′-ACGTAAAAAG GGTATCTAGA ATTATGAAAG (SEQ ID NO.
- the double stranded fragment was cleaved with Xba I and Pst I and ligated in to pTrpABDT1T2 restricted with the same enzymes ( FIG. 2 ).
- the ligation mixture was used to transform E. coli, strain RRI ⁇ M15. After confirming the size of the inserts by PCR, the sequence was verified by cycle sequencing (Amersham Pharmacia Biotech, Uppsala, Sweden). The resulting plasmid was denoted pTrpABDmutT1T2.
- E. coli cells harboring the plasmid encoding ABDmut and also the wild type ABD as a reference were grown over night in shake flasks containing 500 ml Tryptic Soy Broth (30 g/l) supplemented with yeast extract (Difco, USA) (5 g/l) and kanamycin monosulphate (50 mg/l). Since the ABD gene is under control of the tryptophan promoter, the m-RNA production starts when the amino acid is missing in the growth medium. Cells were harvested after 20 hours by centrifugation, 4000 ⁇ g in 10 minutes.
- ABDwt and ABDmut were solubilized in lxHBS (10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% P20) to a concentration of 800 nM and analyzed on BIAcore 2000 (Biacore AB, Uppsala, Sweden).
- lxHBS 10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% P20
- BIAcore 2000 Biacore AB, Uppsala, Sweden
- a BIAcore 2000 instrument (Biacore AB) was used for real time affinity analysis. HSA and IgG were immobilized on two different surfaces of a CM5 sensor chip by amine coupling to the carboxylated dextran layer. This coupling was done according to the manufacturer's recommendation (Biacore AB). The IgG surface was used as a control. The samples were run through a 0.45 ⁇ m filter and injected over the surface in a random order at a flow rate of 5 ⁇ l/min. The results clearly show that ABDwt loses the affinity towards HSA during exposure to alkaline solution whereas the mutated variant that lacks four asparagine residues, has the affinity preserved. The sensorgrams are shown in FIG. 5 .
- K on (1/Ms) K off (1/s) K aff (1/M)
- ABDwt 9.0 ⁇ 10 4 1.3 ⁇ 10 ⁇ 3 6.9 ⁇ 10 7
- ABDmut 1.8 ⁇ 10 4 1.2 ⁇ 10 ⁇ 3 1.5 ⁇ 10 7 K on represents the rate at which the proteins associate, K off the dissociation rate and K aff is the affinity constant which is calculated as the ratio between K on and K off .
- the supernatant was filtered through 0.45 ⁇ m filters (Millipore Corp., Bedford, Mass., USA) and subjected to HSA affinity chromatography (Nygren et al. 1988).
- the amount of eluted protein was estimated by absorbance measurements using the specific absorption constant, a (L/g*cm), and relevant fractions were lyophilized.
- Plasmid pTRPZABDstabT1T2 was constructed from pTRPABDmutT1T2.
- a gene fragment of 233 base pairs, encoding the Z domain was isolated from pRIT45 (Nilsson et al. (1994) Eur. J. Biochem. 224, 1038-108) by XbaI-EcoRI-digestion and ligated into the pTRPABDmutT1T2, which has previously been cut with the same restriction endonucleases.
- the ligation mixture was used to transform E. coli, strain RRI ⁇ M15.
- the resulting plasmid contained a gene encoding the fusion protein Z-ABDstab and was denoted pTRPZABDstabT1T2.
- ABDstab and Z-ABDstab are as follows: ABDstab ATGAAAG CAATTTTCGT ACTGAATGCG CAACACGATG AAGCCGTAGA CGCGAATTCA (SEQ ID NO. 11) TTAGCTGAAG CTAAAGTCTT AGCTCTGAGA GAGCTCGACA AATATGGAGT AAGTGACTAT TACAAGGATC TAATCGATAA AGCCAAAACT GTTGAAGGTG TAAAAGCACT GATAGATGAA ATTTTAGCTG CATTACCTTA A Z-ABDstab ATGAAAG CAATTTTCGT ACTGAATGCG CAACACGATG AAGCCGTAGA CAACAAATTC (SEQ ID NO.
- Examples 9 and 10 show that it is possible to randomise a surface on the already stabilised ABD-molecule, for example a surface that does not take part in the HSA-binding and thereby create a molecule that is able to bind any target of choice and also retains affinity towards HSA.
- Three different plasmid gene constructs were assembled by PCR based mutagenesis, each encoding ABDmut protein variants containing three alanine substitutions: pTrpABDmut22-25-26 containing alanine substitutions at positions 22, 25 and 26 of the ABDmut domain; pTrpABDmut29-30-33 containing alanine substitutions at positions 29, 30 and 33 of the ABDmut domain, and pTrpABDmut54-57-58 containing alanine substitutions at positions 54, 57 and 58 of the ABDmut domain.
- pTrpABDmutT1T2 As a template for the PCR mutagenesis plasmid pTrpABDmutT1T2 was used (see Example 1).
- the plasmid encodes the gene for ABDmut under transcriptional control of the tryptophan promoter.
- Exchange of amino acids 22, .25 and 26 for alanine was done by an ordinary PCR mutagenesis using the primer T1T2 (see Example 1) and LIMA 12: 5′-GTAGACGCGA ATTCATTAGC (LIMA12) (SEQ ID NO. 6) TGCTGCTAAA GCAGCTGCTC TG-3′
- the PCR mutagenesis for the other two constructs was performed in two steps.
- the mutations were introduced and in the second PCR, the fragments from the first PCR amplification were mixed and subjected to Taq DNA polymerase assisted double strand DNA synthesis (the same strategy as in FIG. 1 ), followed by amplification using flanking primers (SOHO8 and T1T2 (see Example 1)).
- the primers used in the PCR for exchange of amino acids 29, 30 and 33 for alanine were: (SEQ ID NO. 7) 5′-ACTCCATATG CGTCGAGCGC TGCCAGAGCT-3′ (LIMA13) (SEQ ID NO.
- the double stranded PCR product was cleaved by restriction endonucleases EcoRI and PstI and for the other two mutants XbaI and PstI was used.
- the different fragments were ligated into pTrpABDT1T2 restricted with the same enzymes, resulting in a replacement of the wild type ABD domain gene for the three different ABDmut triple mutants.
- the respective mixtures were used to transform E. coli, strain RRI ⁇ M15. After confirming the size of the inserts the sequences were controlled by cycle DNA sequencing (Amersham Pharmacia Biotech, Uppsala, Sweden).
- the resulting plasmids were denoted pTrpABDmut22-25-26, pTrpABDmut29-30-33, and pTrpABDmut54-57-58, respectively.
- the DNA sequences of the three triple mutants are as follows: ABDmut22-25-26 ATGAAAG CAATTTTCGT ACTGAATGCG CAACACGATG AAGCCGTAGA CGCGAATTCA (SEQ ID NO. 13) TTAGCTGCTG CTAAAGCAGC TGCTCTGAGA GAGCTCGACA AATATGGAGT AAGTGACTAT TACAAGGATC TAATCGATAA AGCCAAAACT GTTGAAGGTG TAAAAGCACT GATAGATGAA ATTTTAGCTG CATTACCTTA A ABDmut29-30-33 ATGAAAG CAATTTTCGT ACTGAATGCG CAACACGATG AAGCCGTAGA CGCGAATTCA (SEQ ID NO.
- ABDmut29-30-33, and ABDmut54-57-58 proteins ABDmut22-25-26, ABDmut29-30-33, and ABDmutS4-57-58 proteins were produced and purified as described in Example 2.
- HSA was immobilised on a sensor chip surface of a CM5 sensor chip by amine coupling to the carboxylated dextran layer.
- a sensor chip surface containing IgG was used as control. This coupling was done according to the manufacturers recommendation (Biacore AB).
- the samples of the three proteins were run through a 0.45 ⁇ m filter and injected over the surface in a random order at a flow rate of 20 ⁇ l/min.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- The present invention relates to affinity separation and to ligands for use therein.
- Affinity separations generally take place on an affinity chromatography column and take advantage of the potentially highly specific nature of interactions involving biomolecules, especially proteins. Other possible separation methods include membrane filtration, two-phase extraction, fluidised beds, expanded beds and magnetic bead separation (Scopes, R. K. Protein Purification, Principles and Practice, 3rd Ed. ISBN 0-387-94072-3). Interactions include protein-protein, protein-nucleic acid, enzyme-substrate, receptor-ligand (e.g. hormone) protein- carbohydrate and protein-metal interactions. Generally, affinity separation is based on the biologically important binding interactions that occur on protein surfaces, such as that between an enzyme and its substrate, between nucleic acid and a DNA binding protein or between antigen and antibody. Either one of a pair of binding partners can be immobilised, e.g. by covalent bonding to an insoluble matrix in an affinity column in order to assay for or purify its binding partner. The very selective nature of interactions between or involving affinity binding molecules, particularly proteins makes them ideal for purification/separation techniques and for many applications, affinity chromatography involving an immobilised protein ligand is preferred over ion-exchange or gel-filtration chromatography.
- If a sample is added to a column which carries immobilised on a solid matrix a specific binding partner to a target molecule in the sample, the target molecule will be retained in the column while the majority of the non-target molecules will simply run through. A solution, typically containing a gradually decreasing pH can be added to the column to wash through firstly any non-specifically bound molecules and finally to elute the target molecule. The target molecule, having the highest affinity for the immobilised ligand, will be the last molecule to be washed off the column and it is therefore the final fractions which will contain the highest concentration of the target molecule and can then be used in a further purification/concentration step or be assayed directly or indirectly for the presence of the target molecule.
- Medicine and research in the biochemical and biotechnological fields generally, has created a demand for ever purer samples of organic and biological molecules and thus for strategies which can provide samples of high purity as quickly and cheaply as possible.
- As well as satisfying a need to obtain pure samples of proteins and other molecules, affinity separation is important in assaying samples quantitatively and qualitatively for a target molecule. This may be important, for example, when blood or urine samples are being assayed for molecules indicative of a disease such as a metabolic disorder or even the presence of non-naturally occurring substances, narcotics, steroid derivatives etc.
- An affinity chromatography column, complete with its solid affinity matrix, can be expensive and clearly it is desirable to be able to re-use the column several times, i.e., to complete a number of runs before it has to be discarded due to reduced ability of the immobilised ligand to bind a target molecule or to a reduced specificity of binding. In order to achieve a set of results which can be directly compared and to clear the column of non-specific and specifically bound molecules before performing another run, it is necessary to clean the column. The recognised standard for cleaning and sanitizing separation media and systems is NaOH, often in combination with NaCl. An applied 0.1-1.0 M NaOH solution is able to remove viruses, bacteria, nucleic acid, proteins, yeasts, endotoxins, prions and other contaminating agents. The NaOH contact time may vary, between 30 minutes and 1 hour is typical, and removal from the system is monitored by simple in-line pH and conductivity measurements.
- However, the ability of the separation media to withstand these rather harsh sanitizing conditions depends on the functional groups of the attached ligand(binding partner), attachment chemistries, and the stability of the base matrices to alkaline conditions. Proteins are sensitive to extreme pH, such as is experienced during NaOH cleaning and, generally speaking, this will adversely affect the effectiveness of protein-based affinity media. Thus, although protein based affinity separation has advantages over ion exchange and gel-filtration chromatography due to its good specificity, these other less specific techniques are not adversely affected by standard cleaning methods.
- The sensitivity of proteins to alkaline pH is primarily due to deamidation of asparagine and glutamine residues, particularly asparagine residues. Deamidation of asparagine results in the formation, via a cyclic imide intermediate, of isoaspartate and aspartate, usually in the ratio of 3:1 to 4:1. This reaction does take place at physiological pH but is far faster at alkaline pH such as present in a chromatography column which is being cleaned by an NaOH solution. The isoaspartyl form is characterised by an atypical amide bond between the β-carboxyl of aspartate and the α-nitrogen of the C-flanking amino acid. This results in an extra —CH2— in the backbone of the protein as well as a free α-carboxyl group. Cleavage of the peptide backbone may occur as a result of the deamidation and the protein may lose its activity due to a structural change in the whole protein, or merely a small change in a sensitive region such as the active or binding site. The susceptibility of asparagine residues to deamidation is sequence and conformation dependent, Asn residues at Asn-Gly and Asn-Ser sites being particularly vulnerable.
- It is a serious problem when an affinity chromatography column has been set up with a protein immobilised on an insoluble support within it and the necessary cleaning process between runs results in reduced efficacy of the system. As well as hastening the end of the absolute useful life of the column, if successive washes decrease the ability of the immobilised protein to capture its binding partner from a sample, comparisons between runs where the concentration of an analyte in a series of samples is measured become meaningless. There is therefore a need for a method of affinity separation wherein the immobilised protein is less susceptible to standard cleaning methods, particularly to alkaline pH.
- Thus, in one aspect, the present invention provides a method of affinity separation wherein the affinity ligand is an immobilised proteinaceous ligand wherein one or more of its asparagine residues has been modified.
- The term “modified” includes deletion of the asparagine residue or replacement of it with a less alkaline-sensitive amino acid, or wherein the asparagine residue has been modified by substitution (i.e. chemical substitution of one or more groups) or other chemical derivitisation, e.g. by a protecting group. Replacement of one or more asparagine residues with a less alkaline-sensitive amino acid is preferred.
- By affinity separation is meant any purification or assaying technique which involves the addition of a sample containing a target analyte to a solid which carries on it a specific binding partner to the analyte. Gravity or other means allows the sample to pass through or across the solid, and the interaction between the analyte and its specific binding partner immobilised on the solid means that the analyte will be retained on the solid while the rest, or most of the rest, of the sample passes through the system. The separation may conveniently be carried out on an affinity chromatography column. The solid is preferably arranged in a column, so that the sample can be added to the top and the non-target part of the sample runs off. An eluant such as a salt solution or a change of pH can be used to displace the specifically bound analyte which can then be collected in a number of aliquots in a controlled manner.
- An “affinity ligand” is thus a target-specific binding partner, which can be used in an affinity separation process.
- ‘Analyte’ is used to refer to any molecule or fragment of a molecule, proteinaceous or otherwise, in a sample which is capable of binding specifically to the immobilised ligand.
- The term ‘specific binding partner’ may include a molecule or a group of related molecules and any one of these molecules may also bind ‘specifically’ to one or more other molecules. Thus, the term does not imply that any one immobilised ligand or analyte can have only one binding partner, rather that binding is specific to the extent that most other molecules will not bind with the same affinity or with the same stringency, particularly that other non-target molecules in a given sample will have a much lower affinity. Purification by affinity separation is often of the order of several thousand-fold because of the high affinity between biologically specific binding partners.
- All types of affinity separation which include an immobilised proteinaceous ligand can be used in the method of the invention, and suitable matrices (i.e. solid support) known for use with particular ligands are known in the art, typically based on chromatography using agarose, polacrylamide, silica, polyvinyl styrene, dextran or other polymers. Any of the solid support known in the art for separation or immobilisation processes may be used, as indeed may any of the methods known in the art for attaching molecules such as affinity ligands to solid supports. The proteinaceous ligands are usually attached to the matrix by a coupling agent such as cyanogen bromide, epichlorohydrin, bisoxirane, divinyl sulfone, carbonyl diimidazol, N-hydroxysuccinimide, tosyl/tresyl chloride, epichlorohydrine, carbodiimide, glutaraldehyde, hydrazine, oxirane and also carboxyl or thiol activated matrices and again such coupling agents and coupling chemistries are well known in the art and widely described in the literature (Jansson, J. C. and Ryden, L. Protein purification, 2nd Ed. pp 375-442, ISBN 0-471-18626-0). Various derivatives of matrices which allow straightforward immobilization include CNBr-activated Sepharose 4B, AH-Sepharose 4B and CH-Sepharose 4B and Epoxy-activated Sepharose 6B (Pharmacia).
- The proteinaceous affinity ligand may be a molecule having a protein component, which may function as a “specific binding partner” as defined above. Thus, glycoproteins or protein-lipid complexes or indeed proteins with prosthetic groups may be used as the affinity ligand which is modified according to the present invention. Protein molecules are, however, preferred. The term “protein” is used herein broadly to include any molecule having a polypeptide or peptide structure. In other words, as used herein, a “protein“is made up of a chain of amino acids, and the term does not imply any particular conformational (i.e. tertiary structure) or other requirement.
- Suitable amino acids to replace asparagine include any of the other 19 standard naturally occurring amino acids, although cysteine and glutamine would not be preferred. Preferred substituting amino acids include lysine, aspartic acid and leucine. Non-naturally occurring amino acids and amino acid derivatives which are well known to the man skilled in the art could also be used to replace asparagine residues. Significant improvements in the stability of the immobilised protein and thus the efficacy of the column after cleaning can be observed when just one asparagine is substituted by a less alkaline sensitive residue but preferably 2, 3 or more, or even all of the asparagine residues are substituted.
- A “less alkaline-sensitive amino acid” is one which is less susceptible to degradation under alkaline conditions than Asn, when compared using techniques, methods and conditions known in the art. Such conditions may, for example, be the column washing conditions discussed above, or any other alkaline conditions used in the art to study protein stability or degradation e.g. deamidation as discussed above. A “less alkaline-sensitive” amino acid may thus be any amino acid other than Asn, and more preferably other also than Gln and Cys. Conveniently, alkaline-sensitivity may be compared by replacing a given Asn residue in a protein molecule with a substitute amino acid, or by chemically modifying or derivatising the said Asn residues, and then comparing stability in alkaline conditions (e.g. column wash conditions) with the unmodified protein.
- As indicated above, the sensitivity of a particular asparagine residue to deamidation will depend on the configuration of the protein, it being particularly important to replace those residues which are on the surface of the three dimensional structure of the protein and thus particularly exposed to the alkaline conditions. It is the overall stability of the ligand which is of most importance and it is desirable to retain the specificity of the interaction between the immobilised ligand and its binding partner, therefore, preferably it is the asparagine residues not involved in the ligand-analyte interaction which are replaced.
- The “asparagine modified” proteinaceous affinity ligand (hereinafter the “modified protein”) may be made by any method known to the skilled man. Standard techniques for site-directed mutagenesis of nucleic acids are described, for example, in the laboratory manual entitled Molecular Cloning by Sambrook, Fritsch and Maniatis. A preferred technique involves PCR mutagenesis, where primers which incorporate the necessary mis-match base pairs to generate the desired mutations are used in a first round of PCR. In the second run, the fragments from the first run are mixed and the polymerase is able to fill in the strands. The resulting double stranded fragment can be ligated into a plasmid which is then used to transform E. coli. The protein can by synthesised in vitro without using a biological host and in this case non-naturally occurring amino acids can be introduced.
- As well as the many general uses of affinity separation indicated previously, of particular interest in the present case is the use of affinity separation with ligands which have been made by randomisation (random mutagenesis) of a particular protein to generate ligands with novel, modified or enhanced binding characteristics. These proteins are referred to as combinatorial proteins. Such a technique typically involves random mutagenesis of a target protein, expression of the full library of these variants, e.g. on the surface of filamentous bacteriophage, followed by selection of a protein exhibiting the desired binding characteristics, this selection typically involving a binding reaction between the variant protein and an immobilised ligand (binding partner) i.e. target molecule for the protein, e.g. target analyte. The mutagenesis is random in that the resulting amino acid encoded by any particular codon is not generally pre-determined but the positions where mutations are to be introduced are generally identified in advance. The mutagenesis may involve amino acid substitution deletion, or addition (e.g. insertion).
- The use of an expression system such as surface display on phage provides a crucial link between genotype and phenotype; there is a self-contained unit which can be selected on the basis of its specific binding interactions and which also carries the nucleic acid encoding for the protein responsible for the observed binding characteristics. This enables expression in useful amounts of the protein selected for its binding characteristics, such expression typically taking place in a transformed bacterial host.
- The protein, selected by its ability to bind to an immobilised ligand (e.g. a desired target molecule (analyte)), is then itself used in affinity separation (i.e. as the affinity-ligand). It is immobilised and used to purify or assay for a target molecule in a sample, typically the same ligand which was used to select the protein in the first place. In this way, a protein from a library of variants can be selected for its ability to bind e.g. insulin, using a column with insulin immobilised on a matrix therein and the selected protein can then be used to test samples for the presence of insulin.
- As well as testing for the presence of a target molecule, the affinity separation methods of the invention provide excellent purification methods, yielding samples of a target molecule having good purity. In particular, the methods of the invention will still produce pure samples after many cycles of the separation system, e.g. after many runs, with washing, of a column. Such samples produced by the methods of the invention constitute further aspects of the invention.
- If a protein is stabilised by replacing one or more of its asparagine residues with a less alkaline sensitive amino acid prior to the randomisation and selection steps described above, then its useful life as an affinity ligand will be extended due to its ability to withstand the harsh conditions such as high pH which are experienced when an affinity column is washed between runs.
- Therefore, a further aspect of the present invention comprises a combinatorial protein wherein in a step separate from the randomisation step (i.e. the step used to generate the combinatorial protein by randomisation of an “origin” or “source” or “starting protein”), the stability of the protein in alkaline conditions has been increased by modifying one or more of its asparagine residues (preferably by replacing one or more of its asparagine residues with a less alkaline sensitive amino acid).
- Nucleic acid molecules encoding such a protein as well as cells expressing the protein constitute further aspects of the present invention.
- The randomisation may itself result in substitution of asparagine residues but this aspect of the invention is concerned with proteins which have also been specifically modified to replace one or more asparagine residues in order to increase stability. The protein can be stabilised before or after the randomisation or at the same time but preferably the stabilising modifications will be introduced before the randomisation takes place. If stabilisation is performed before randomisation, it need only be performed once, and by selecting from the library of randomised variants against a number of ligands, several stabilised proteins with different binding characteristics can be obtained. If the stabilisation is performed after selection for a particular binding affinity, then there is a risk that some affinity would be lost as a result of the stabilising substitutions.
- Techniques for construction of a combinatorial library of protein molecules and subsequent selection to obtain proteinaceous ligands having desired binding characteristics are known in the art (Nygren, P. and Uhlen, M. Current Opinion in Structural Biology (1997) 7: 463-469). Generally, a protein molecule, perhaps having intrinsic beneficial properties such as temperature or pH insensitivity, is used as a scaffold and a combinatorial library is then constructed via random but targeted amino acid substitutions (or other mutations) of that protein molecule, in order to produce a library of molecules having different binding characteristics. Surface residues are generally targeted for random mutagenesis.
- Suitable protein scaffolds may simply be linear peptides but preferably the scaffold will possess a folded three dimensional structure which has the potential for higher affinities and is less susceptible to proteolytic degradation. Rather than designing a scaffold de novo, naturally existing proteins or domains are usually selected for further engineering. For the avoidance of doubt, it is to be noted that throughout this specification the word “protein” is used to refer to whole protein molecules as well as domains or fragments thereof, polypeptides or peptides.
- The choice of protein scaffold depends on several parameters including an ability to be effectively expressed in a desired host organism e.g E. coli when the randomised protein is to be displayed as a fusion protein with a filamentous.phage coat protein. The protein should also comprise sufficiently large regions on its surface which are tolerant to substitution (or insertion or deletion etc.) without losing the overall three dimensional structure. If the library is to be produced synthetically, a small overall size is a prerequisite. Where the selected scaffold protein has a binding function, amino acid residues involved in that interaction may be a target for randomisation. Randomisation may be performed in order to enhance known binding properties or to develop ligands with new specificities.
- Suitable scaffold molecules are discussed in Nygren et al. (1997) and include cyclic peptides having 40 or more residues in a constrained sequence, immunoglobulin-like scaffolds including Fv or single-chain (scFv) domains, bacterial receptors such as the 58-residue one-domain Staphylococcal protein A (SPA) analogue Z (the “Z Domain” being a derivative of the B domain of SPA), or other domains or analogues of SPA, DNA-binding proteins particularly zinc fingers and protease inhibitors. All these molecules can be stabilised by substituting one or more native asparagine residues with a less alkaline sensitive amino acid before a combinatorial library of the pre-stabilised protein is made.
- Of particular interest is the bacterial receptor domain Z (Nord, K., Nilsson, J., Nilsson, B., Uhlén, M. and Nygren, P. Protein Engineering (1995) 8, 6, 601-608). This paper by Nord et al. describes a suitable method of constructing a combinatorial library of protein molecules which can be applied to a range of scaffold molecules. The method described is solid-phase-assisted and based on the stepwise assembly of randomised single-stranded oligonucleotides.
- Selection from a generated protein library can be performed in a number of different ways known in the art, including bead immobilised libraries (McBride, J. D., Freeman, N., Domingo, G. J. and Leatherbarrow, R. J., J. Mol. Biol. [1996] 259: 819-827), fusions to DNA-binding proteins (Schatz, P.J., Biotechnology [1993]11, 1138-1143) and when displayed on bacteria (Lu, Z., Murray, K. S., Van Cleave, V., LaVallie, E. R., Stahl, M. L. and McCoy, J. M. Biotechnology [1995], 13 366-372) or phage (Clackson, T. and Wells, J. TIBTECH (1994) 12, 173-183) as well as yeast cells,(Boder, E.T. and Wittrup, K. D., Nature Biotechnology (1997) 15, 553-557) and in viral systems (Ernst, W., Grabher, R., Wegner, D., Borth, N., Graussauer, A. and Katinger, H. Nucleic Acids Research (1998) 26, 1718-1723 and Grabher, R., Ernst, W., Doblhoff-Dier, O., Sara, M. and Katinger, H. BioTechniques (1997) 22, 730-735).
- International Patent Application, publication No. WO 95/19374 describes the generation of a combinatorial library of Z-variants, see in particular Example 4. This application discusses on page 12 the advantages of the Z domain as an affinity ligand in the purification of recombinant proteins, as it is relatively stable in the harsh environment of an affinity column during cleaning. The present invention offers further benefits in that the Z domain can be stabilised to alkaline pH by replacement of asparagine residues. According to the present invention it is proposed to stabilise the native Z domain before the combinatorial library is prepared.
- Thus in a further aspect, the present invention provides a method of preparing a combinatorial library of protein molecules wherein the protein has been rendered less sensitive to alkaline pH by modification of one or more of its asparagine residues before it is randomised (preferably by replacement of one or more of its asparagine residues).
- In a yet further aspect of the present invention is provided a method of phage display wherein a protein expressed on the phage surface has had one or more of its asparagine residues modified (preferably by replacement with a less alkaline sensitive residue) in a step separate to any modifications introduced in order to modify binding characteristics of the protein.
- A further aspect of the present invention comprises a method of making a stabilised combinatorial protein comprising the steps of:
-
- a) modification of asparagine residues within a protein molecule to increase stability of the protein in alkaline conditions; and
- b) randomisation of the protein molecule to modify its binding characteristics.
- Modification in step a) will preferably comprise replacement of asparagine residues with other less alkaline sensitive amino acids, Step a) is preferably carried out before step b).
- As well as a protein molecule which has been randomised and stabilised, the present invention also relates to fusion proteins comprising a stabilised part and a randomised part, such proteins being useful in certain applications. In particular, this technique enables the development of a stable framework which can have attached thereto a variable region with specific binding characteristics. The variable region can be prepared by randomisation techniques as discussed above and a protein molecule having desired binding characteristics can be selected from the library of variants, for example by phage display and affinity chromatography. This randomised protein can then be expressed as a fusion protein, e.g. in E. coli, together with a protein molecule which has already been engineered to improve its stability to alkaline conditions by replacing one or more of its asparagine residues with other less alkaline sensitive residues.
- The fusion protein can be used as an immobilised ligand in affinity chromatography, giving the benefits of a generally stable molecule provided by the framework part as well as a pre-selected binding affinity provided by the randomised part. Such a system may enable the use of a small protein molecule during the randomisation and selection stage as important protein-like characteristics (as opposed to peptide characteristics) are provided by the stabilised part. The same stabilised part can be used together with a variety of different randomised molecules and vice versa. Suitable protein molecules to perform as the stabilised framework part of the fusion peptides include Albumin Binding Protein (ABD); the bacterial receptor domain Z is a suitable molecule for randomisation in this context.
- Thus the present invention also provides a fusion protein comprising a first part wherein one or more naturally occurring asparagine residues have been modified (preferably replaced by an amino acid residue less sensitive to high pH) and a second part being a randomised protein molecule selected for its specific binding properties.
- Nucleic acid molecules encoding such a protein as well as cells expressing the protein constitute further aspects of the present invention.
- A further aspect of the present invention comprises a method of stabilising an affinity ligand by modifying one or more of its asparagine residues (preferably the affinity ligand is stabilised by replacing one or more of its asparagine residues with an amino acid residue less sensitive to alkaline pH).
- A still further aspect comprises the use of a protein molecule stabilised by modification of one or more of its asparagine residues in surface display or in affinity chromatography.
- The term ‘surface display’ refers to the technique involved in selection of a protein from a library of molecules which are presented (displayed) in a manner which enables differentiation between the protein molecules on the basis of their binding characteristics. Surface display is typically performed on the surface of filamentous bacteriophage (phage display) but display can also be on the surface of bacteria, yeast cells or using viral systems. Any “surface display” technique known or proposed in the art, may be used according to the present invention.
- A preferred affinity ligand for use in the methods of the invention is Albumin Binding Protein (ABD), a protein domain with affinity towards human serum albumin (HSA). It is derived from a cell wall anchored bacterial receptor protein from Streptococcus G148. It is of particular use as an affinity ligand for the purification of human serum albumin (HSA). The wild type sequence of this protein has four asparagine residues, enhanced stability is observed when just one of these residues is substituted but preferably all four residues are replaced by less alkaline sensitive residues. The wild type amino acid sequence of ABD is: LAEAKVLANRELDKYGV-SDYYKNLINNAKTVEGVKALIDEILAALP the asparagine residues have been indicated in bold. The hyphen simply indicates that other molecules in the same family have an additional amino acid in this position. This sequence excludes the 19 amino acid N-terminal ‘tail’ shown in
FIG. 3 . Throughout the text particular amino acids of ABD are identified by their position in the full sequence (including the 19 amino acid ‘tail’) as presented inFIG. 3 . Thus, the first asparagine residue of ABDwt which may be stabilised is in position 28 (Asn28). Stabilised versions of ABD for use in the methods of the invention may incorporate some, all or none of the 19 amino acid N-terminal tail. - Stabilised ABD may, as discussed above, be further subjected to randomisation to create a protein (i.e. a combinatorial protein) having e.g. modified binding characteristics for HSA and/or that is able to bind any target of choice and also retains affinity towards HSA. The randomisation may involve mutagenesis of the same, or preferably different, residues modified in the stabilisation step. Such derivatives of ABD (e.g. mutants created by random or directed mutagenesis) are also included within the scope of the invention.
- Thus a further aspect of the present invention is Albumin Binding Protein(ABD) or fragments or derivatives thereof wherein one or more native asparagine residue have been replaced by a less alkaline sensitive amino acid. Nucleic acid molecules encoding such a protein as well as cells expressing the protein constitute further aspects of the present invention.
- In a particularly preferred embodiment Asn28 is replaced by leucine, Asn42 by aspartic acid, Asn45 by aspartic acid and Asn46 by lysine (referred to as ABDmut herein). ‘ABDmut’ is used to refer to proteins incorporating some, all or none of the 19 amino acid N-terminal tail. Typically, if ABDmut is part of a fusion protein, e.g. with domain Z, then only part or none of the N-terminal tail will be present. Asparagine is the most alkaline sensitive amino acid and so any other amino acid residue could be used to replace it and an increase in stability would be expected. It may be of assistance to compare the sequences of other homologous proteins, which are found in other species or.perform the same role, to identify suitable amino acids to be used in the substitution.
- In a method suitable for the stabilisation of other affinity ligands, the modifications were introduced by PCR mutagenesis. Firstly mismatched primers are used to introduce the mutations and then the fragments from the first run of PCR are mixed and the polymerase allowed to fill in the strands. The double stranded fragment of ABD incorporating the modifications is cleaved with restriction enzymes and ligated into a plasmid restricted with the same enzymes, which is then used to transform E. coli, the expression system for the protein.
- Preferably, the affinity ligand purified (i.e. obtained) according to the methods of the invention retains more than 80%, preferably more than 95%, of its normal binding capacity after 20 rounds of treatment with 0.5M NaOH.
- The invention will be further described in the following non-limiting Examples in which:
-
FIG. 1 is a schematic description of the PCR-mutagenesis step according to the invention; -
FIG. 2 shows the cloning of the gene construct; -
FIG. 3 is the amino acid sequence of wild type ABD and a mutated alkaline resistant variant of it, the full sequence of the mutated variant is designated herein as SEQ ID NO. 1; -
FIG. 4 shows an SDS-PAGE (4-20%) under reducing conditions.Lanes 1 and 2 show purified ABD and ABDstab respectively. The third lane shows a molecular weight marker (from top 94, 67, 43, 40, 20.2 and 14.4 kDa respectively). In order to check the selectivity of the mutated ABD, E. coli disintegrate was spiked with HSA (lane 4) and loaded onto the column.Lanes Lane 8 shows an HSA reference; -
FIG. 5 shows Sensorgrams from the BIACore showing the binding characteristics of (A)ABDwt and (B)ABDmut before and after treatment with 0.5M NaOH for 24 hours; -
FIG. 6 is a diagram showing the capacity of two affinity matrices, ABDwt and ABDmut respectively, after several rounds of treatment with 0.5M NaOH; and -
FIG. 7 shows sensorgrams from the Biacore experiment described in Example 10 showing the binding characteristics of ABDmut and the three different triple-mutants thereof, Response Unit (RU) v Time (S); A ABDmu; ▴ 29-30-33A; □ 54-57-58 A; ▪ 22-25-26 A. - Throughout the Examples ABDstab and ABDmut are used synonymously.
- As a template for the PCR mutagenesis pTrpABDT1T2 was used (Kraulis et al. (1996) FEBS Lett. 378, 190-194). The plasmid encodes the gene for ABDwt under control of the tryptophan promoter. The PCR mutagenesis was performed in two steps. In the first PCR the mutations was introduced and in the second round of PCR, the fragments from the first run were mixed and the polymerase was allowed to fill in the strands (
FIG. 1 ). The primers used in the first PCR were:5′-ACGTAAAAAG GGTATCTAGA ATTATGAAAG (SEQ ID NO. 2) C-3′ (SOHO8) 3′-CAGAATCGAG ACTCTCTCGA GCTGTTTATA (SEQ ID NO. 3) CC-5′ (SOHO6) 5′- GAGAGAGCTC GACAAATATG GAGTAAGTGA (SEQ ID NO. 4) CTATTACAAG GATCTAATCG ATAAAGC-3′ (SOHO7) 3′-CCGCCTACTC TCTTCTAAAA GTCG-5′ (SEQ ID NO. 5) (T1T2) - The double stranded fragment was cleaved with Xba I and Pst I and ligated in to pTrpABDT1T2 restricted with the same enzymes (
FIG. 2 ). The ligation mixture was used to transform E. coli, strain RRIΔM15. After confirming the size of the inserts by PCR, the sequence was verified by cycle sequencing (Amersham Pharmacia Biotech, Uppsala, Sweden). The resulting plasmid was denoted pTrpABDmutT1T2. - E. coli cells harboring the plasmid encoding ABDmut and also the wild type ABD as a reference were grown over night in shake flasks containing 500 ml Tryptic Soy Broth (30 g/l) supplemented with yeast extract (Difco, USA) (5 g/l) and kanamycin monosulphate (50 mg/l). Since the ABD gene is under control of the tryptophan promoter, the m-RNA production starts when the amino acid is missing in the growth medium. Cells were harvested after 20 hours by centrifugation, 4000×g in 10 minutes. After resuspending the cells in 30 ml TST (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20) they were fractured by sonication. After that a centrifugation step was performed, approximately 40,000×g in 20 minutes. The supernatant was filtered (0.49 μm). The soluble protein was isolated by affinity chromatography on human serum albumin (HSA) Sepharose as described by Stahl et al. (1989) J. Immunol. Meth. 124, 43-52. The protein content in eluted fractions was measured by absorbance at 280 nm and relevant fractions were collected and lyophilized. Both proteins are of high purity after a single step purification and migrate in accordance with their molecular masses.
- In order to examine the stability of ABDwt and ABDmut, the binding characteristics were analysed before and after treatment with 0.5 M NaOH in room temperature for 24 hours. Both ABDwt and ABDmut were solubilized in lxHBS (10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% P20) to a concentration of 800 nM and analyzed on BIAcore 2000 (Biacore AB, Uppsala, Sweden). In order to determine the activity change after exposure to a very alkaline environment, the proteins were solubilized in 0.5 M NaOH. After incubation in NaOH for 24 hours, the samples were run through a NAP-10 column (Amersham Pharmacia Biotech, Uppsala, Sweden) equilibrated with 30 mM NH4Ac. The protein containing samples were lyophilized and resolubilised in lxHBS to a concentration of 800 nM in order to be analyzed in the BIAcore 2000.
- BIAcore Analysis
- A BIAcore 2000 instrument (Biacore AB) was used for real time affinity analysis. HSA and IgG were immobilized on two different surfaces of a CM5 sensor chip by amine coupling to the carboxylated dextran layer. This coupling was done according to the manufacturer's recommendation (Biacore AB). The IgG surface was used as a control. The samples were run through a 0.45 μm filter and injected over the surface in a random order at a flow rate of 5 μl/min. The results clearly show that ABDwt loses the affinity towards HSA during exposure to alkaline solution whereas the mutated variant that lacks four asparagine residues, has the affinity preserved. The sensorgrams are shown in
FIG. 5 . - Also, an analysis of the kinetic parameters was performed for the proteins that still remained active. This was done by analysing the binding behaviour in different concentrations and thereafter calculating the binding constants by using BIAevaluation 2.1 software (BIAcore AB). The concentrations used were 40-220 nM for ABDwt, 200-600 nM for ABDmut and 800-1250 nM for the NaOH treated ABDmut. The results are shown in table 1 below.
TABLE 1 Kon (1/Ms) Koff (1/s) Kaff (1/M) ABDwt 9.0 × 104 1.3 × 10−3 6.9 × 107 ABDmut 1.8 × 104 1.2 × 10−3 1.5 × 107
Kon represents the rate at which the proteins associate,
Koff the dissociation rate and Kaff is the affinity constant which is calculated as the ratio between Kon and Koff.
-
- Kon represents the rate at which the proteins associate,
- Koff the dissociation rate and Kaff is the affinity constant which is calculated as the ratio between Kon and Koff.
- In order to evaluate the usability of the stabilized HSA-binding protein in biotechnology, two affinity chromatography matrices were prepared; one with the unmutated protein (ABDwt) as a control and the other with the mutated ABD (ABDmut). The matrix used was Sepharose 4B (Amersham Pharmacia Biotech, Uppsala, Sweden) with carbodiimide CMC (Sigma Aldrich, Sweden) as the coupling reagent. ABDwt (4.5 mg) and ABDmut (8.5 mg) were dissolved in 9 ml water separately. 3.5 and 5.0 ml gel was added to ABDwt and ABDmut solutions respectively. Finally 0.38 g of CMC was added to the solutions and they were incubated at room temperature over night. The gels were packed on HR columns (d=5 mm, h=43 mm) and pulsed with 0.5 M ethanolamine, 0.5 M NaCl, pH 8.3 in order to inactivate the matrix and 0.1 M NaAc, 0.5 M NaCl,
pH 4 in order to wash unbounded proteins out. After this, the columns were ready to use for affinity purification of HSA. - To investigate if the selectivity of the mutated protein towards HSA was retained after exchanging four amino acids, a capture experiment was done. A culture of E. coli cells grown over night was fractured by sonication, centrifuged at 40,000×g and filtered through a 0.45 μm filter. The soluble fraction of the E. coli lysate was mixed with pure HSA and the mixture was applied on the ABDmut affinity column. After washing the column, the bound material was eluted by lowering the pH to 2.8 as described by Stahl et al., (1989) supra. As can be seen in
FIG. 4 , the selectivity is retained in the mutated variant of ABD. - In order to explore the difference between the ABDwt column and the ABDmut column in respect of stability against alkaline treatment, both columns were repeatedly washed with 0.5 M NaOH. By using the AKTA explorer the columns were loaded with HSA, the protein was eluted by lowering the pH (StAhl et al., (1989) supra) and finally both columns were washed with NaOH. This cycle was repeated 15 times and the total time of exposure exceeded 6 hours. The flow rate used was 60 cm/h and the eluted material was collected and analyzed in each round. In
FIG. 6 the decrease in capacity is plotted against the NaOH exposure time. As can be seen in the figure, ABDwt is losing the activity quite fast while the mutated variant is keeping the activity throughout the experiment. These results corroborate with the BIACore data, the mutated variant is much more stable against cleaning-in-place (CIP) treatment than the wild type molecule. - A frozen E. coli RRIΔM15 culture, harbouring the expression vector pTRPZABDstabT1T2 (see Example 8) was used to inoculate 20 ml Tryptic Soy Broth (30 g/l) (Difco, Detroit, Mich., USA) supplemented with 5 g/l yeast extract (Difco) and 50 mg/l kanamycin monsulphate (Labkemi, Stockholm, Sweden). 10 ml of the over night culture was used to inoculate 500 ml of fresh medium. The cells were allowed to grow at 370C and expression of the proteins was induced at mid-log phase (A600nm=1) by adding 3-β-indole acrylic acid (SIGMA-Aldrich, Stockholm, Sweden) to a final concentration of 25 mg/ml. After 24 hours the cells were harvested by centrifugation at approximately 5000 g for 10 minutes followed by resuspension in TST buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1.25 mM EDTA, 0.05% Tween20). The cells were disintegrated by sonication (Vibracell, Sonics & Materials, Danbury, Conn., USA) and centrifuged at 30000 g for 20 minutes. The supernatant was filtered through 0.45 μm filters (Millipore Corp., Bedford, Mass., USA) and subjected to HSA affinity chromatography (Nygren et al. 1988). The amount of eluted protein was estimated by absorbance measurements using the specific absorption constant, a (L/g*cm), and relevant fractions were lyophilized.
- Plasmid pTRPZABDstabT1T2 was constructed from pTRPABDmutT1T2. A gene fragment of 233 base pairs, encoding the Z domain was isolated from pRIT45 (Nilsson et al. (1994) Eur. J. Biochem. 224, 1038-108) by XbaI-EcoRI-digestion and ligated into the pTRPABDmutT1T2, which has previously been cut with the same restriction endonucleases. The ligation mixture was used to transform E. coli, strain RRIΔM15. The resulting plasmid contained a gene encoding the fusion protein Z-ABDstab and was denoted pTRPZABDstabT1T2.
- The DNA sequences of ABDstab and Z-ABDstab (including the region coding for the 19 amino acid N-terminal tail) are as follows:
ABDstab ATGAAAG CAATTTTCGT ACTGAATGCG CAACACGATG AAGCCGTAGA CGCGAATTCA (SEQ ID NO. 11) TTAGCTGAAG CTAAAGTCTT AGCTCTGAGA GAGCTCGACA AATATGGAGT AAGTGACTAT TACAAGGATC TAATCGATAA AGCCAAAACT GTTGAAGGTG TAAAAGCACT GATAGATGAA ATTTTAGCTG CATTACCTTA A Z-ABDstab ATGAAAG CAATTTTCGT ACTGAATGCG CAACACGATG AAGCCGTAGA CAACAAATTC (SEQ ID NO. 12) AACAAAGAAC AACAAAACGC GTTCTATGAG ATCTTACATT TACCTAACTT AAACGAAGAA CAACGAAACG CCTTCATCCA AAGTTTAAAA GATGACCCAA GCCAAAGCGC TAACCTTTTA GCAGAAGCTA AAAAGCTAAA TGATGCTCAG GCGCCGAAAG TAGACGCGAA TTCATTAGCT GAAGCTAAAG TCTTAGCTCT GAGAGAGCTC GACAAATATG GAGTAAGTGA CTATTACAAG GATCTAATCG ATAAAGCCAA AACTGTTGAA GGTGTAAAAG CACTGATAGA TGAAATTTTA GCTGCATTAC CTTAA - Examples 9 and 10 show that it is possible to randomise a surface on the already stabilised ABD-molecule, for example a surface that does not take part in the HSA-binding and thereby create a molecule that is able to bind any target of choice and also retains affinity towards HSA.
- Based on the results from an alanine scan experiment to map the binding site for HSA, gene constructs were made encoding ABDmut (see Example 1) domains containing additional alanine substitutions. These were introduced at positions in the domain pointing away from the identified HSA binding motif, which had been located to the first and second helix and the loop in-between. Three different plasmid gene constructs were assembled by PCR based mutagenesis, each encoding ABDmut protein variants containing three alanine substitutions: pTrpABDmut22-25-26 containing alanine substitutions at positions 22, 25 and 26 of the ABDmut domain; pTrpABDmut29-30-33 containing alanine substitutions at
positions 29, 30 and 33 of the ABDmut domain, and pTrpABDmut54-57-58 containing alanine substitutions at positions 54, 57 and 58 of the ABDmut domain. As a template for the PCR mutagenesis plasmid pTrpABDmutT1T2 was used (see Example 1). The plasmid encodes the gene for ABDmut under transcriptional control of the tryptophan promoter. Exchange of amino acids 22, .25 and 26 for alanine was done by an ordinary PCR mutagenesis using the primer T1T2 (see Example 1) and LIMA 12:5′-GTAGACGCGA ATTCATTAGC (LIMA12) (SEQ ID NO. 6) TGCTGCTAAA GCAGCTGCTC TG-3′ - The PCR mutagenesis for the other two constructs was performed in two steps. In the first PCR amplification the mutations were introduced and in the second PCR, the fragments from the first PCR amplification were mixed and subjected to Taq DNA polymerase assisted double strand DNA synthesis (the same strategy as in
FIG. 1 ), followed by amplification using flanking primers (SOHO8 and T1T2 (see Example 1)). The primers used in the PCR for exchange ofamino acids 29, 30 and 33 for alanine were:(SEQ ID NO. 7) 5′-ACTCCATATG CGTCGAGCGC TGCCAGAGCT-3′ (LIMA13) (SEQ ID NO. 8) 5′-AGCGCTCGAC GCATATGGAG TAAGTGACT-3′ (LIMA14) For the exchange of amino acids 54, 57 and 58 LIMA15 and LIMA16 were used: (SEQ ID NO. 9) 5′-GTGTAGCAGC ACTGGCAGCT GAAATTTTA-3 (LIMA15) (SEQ ID NO. 10) 5′-AAAATTTCAG CTGCCAGTGC TGCTACACCT (LIMA16) TCAAC-3′ - For construction of the plasmid pTrpABDmut22-25-26, the double stranded PCR product was cleaved by restriction endonucleases EcoRI and PstI and for the other two mutants XbaI and PstI was used. The different fragments were ligated into pTrpABDT1T2 restricted with the same enzymes, resulting in a replacement of the wild type ABD domain gene for the three different ABDmut triple mutants. The respective mixtures were used to transform E. coli, strain RRIΔM15. After confirming the size of the inserts the sequences were controlled by cycle DNA sequencing (Amersham Pharmacia Biotech, Uppsala, Sweden). The resulting plasmids were denoted pTrpABDmut22-25-26, pTrpABDmut29-30-33, and pTrpABDmut54-57-58, respectively.
- The DNA sequences of the three triple mutants are as follows:
ABDmut22-25-26 ATGAAAG CAATTTTCGT ACTGAATGCG CAACACGATG AAGCCGTAGA CGCGAATTCA (SEQ ID NO. 13) TTAGCTGCTG CTAAAGCAGC TGCTCTGAGA GAGCTCGACA AATATGGAGT AAGTGACTAT TACAAGGATC TAATCGATAA AGCCAAAACT GTTGAAGGTG TAAAAGCACT GATAGATGAA ATTTTAGCTG CATTACCTTA A ABDmut29-30-33 ATGAAAG CAATTTTCGT ACTGAATGCG CAACACGATG AAGCCGTAGA CGCGAATTCA (SEQ ID NO. 14) TTAGGTGAAG CTAAAGTCTT AGCTCTGGCA GCGCTCGACG CATATGGAGT AAGTGACTAT TACAAGGATC TAATCGATAA AGCCAAAACT GTTGAAGGTG TAAAAGCACT GATAGATGAA ATTTTAGCTG CATTACCTTA A ABDmut54-57-58 ATGAAAG CAATTTTCGT ACTGAATGCG CAACACGATG AAGCCGTAGA CGCGAATTCA (SEQ ID NO. 15) TTAGCTGAAG CTAAAGTCTT AGCTCTGAGA GAGCTCGACA AATATGGAGT AAGTGACTAT TACAAGGATC TAATCGATAA AGCCAAAACT GTTGAAGGTG TAGCAGCACT GGCAGCTGAA ATTTTAGCTG CATTACCTTA A - ABDmut29-30-33, and ABDmut54-57-58 proteins ABDmut22-25-26, ABDmut29-30-33, and ABDmutS4-57-58 proteins were produced and purified as described in Example 2. In order to analyse the binding behaviour of the different triple-mutants a BI core 2000 instrument was used. HSA was immobilised on a sensor chip surface of a CM5 sensor chip by amine coupling to the carboxylated dextran layer. As control, a sensor chip surface containing IgG was used. This coupling was done according to the manufacturers recommendation (Biacore AB). The samples of the three proteins were run through a 0.45 μm filter and injected over the surface in a random order at a flow rate of 20 μl/min. The concentration used was 200 nM and all samples were analysed three times. The resulting sensorgrams show that all three triple-mutants retain their ability to bind HSA (
FIG. 7 ). These results indicate that the nine positions (22, 25, 26, 29, 30, 33, 54, 57, 58) investigated in this study should be possible to subject, either simultaneously or in different combinations, to either directed or random mutagenesis in order to identify novel HSA binding AIBDwt or ABDmut domains with a second activity, such as binding, catalysis or serving as substrate. In addition, residue 62 could also be used for substitutions.
Claims (26)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/000,747 US20050100970A1 (en) | 1998-10-21 | 2004-12-01 | Method of affinity separation and ligands for use therein |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9823071.7 | 1998-10-21 | ||
GBGB9823071.7A GB9823071D0 (en) | 1998-10-21 | 1998-10-21 | A method |
PCT/GB1999/003484 WO2000023580A1 (en) | 1998-10-21 | 1999-10-21 | A method of affinity separation and ligands for use therein |
US09/830,080 US6831161B1 (en) | 1998-10-21 | 1999-10-21 | Method of affinity separation and ligands for use therein |
US11/000,747 US20050100970A1 (en) | 1998-10-21 | 2004-12-01 | Method of affinity separation and ligands for use therein |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/003484 Division WO2000023580A1 (en) | 1998-10-21 | 1999-10-21 | A method of affinity separation and ligands for use therein |
US09/830,080 Division US6831161B1 (en) | 1998-10-21 | 1999-10-21 | Method of affinity separation and ligands for use therein |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050100970A1 true US20050100970A1 (en) | 2005-05-12 |
Family
ID=10841043
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/830,080 Expired - Lifetime US6831161B1 (en) | 1998-10-21 | 1999-10-21 | Method of affinity separation and ligands for use therein |
US11/000,747 Abandoned US20050100970A1 (en) | 1998-10-21 | 2004-12-01 | Method of affinity separation and ligands for use therein |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/830,080 Expired - Lifetime US6831161B1 (en) | 1998-10-21 | 1999-10-21 | Method of affinity separation and ligands for use therein |
Country Status (12)
Country | Link |
---|---|
US (2) | US6831161B1 (en) |
EP (2) | EP1123389B1 (en) |
JP (1) | JP4801258B2 (en) |
AT (1) | ATE305970T1 (en) |
AU (1) | AU773368B2 (en) |
CA (2) | CA2633345C (en) |
DE (1) | DE69927598T2 (en) |
DK (1) | DK1123389T3 (en) |
GB (1) | GB9823071D0 (en) |
NO (1) | NO323994B1 (en) |
WO (1) | WO2000023580A1 (en) |
ZA (1) | ZA200103252B (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008039141A1 (en) * | 2006-09-29 | 2008-04-03 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand comprising domain c from staphyloccocus aureus protein a for antibody isolation |
US20100221844A1 (en) * | 2008-12-24 | 2010-09-02 | Millipore Corporation | Caustic stable chromatography ligands |
US8754196B2 (en) | 2011-06-08 | 2014-06-17 | Emd Millipore Corporation | Chromatography matrices including novel Staphylococcus aureus protein A based ligands |
US9040661B2 (en) | 2010-12-21 | 2015-05-26 | Jsr Corporation | Support for affinity chromatography and method for isolating immunoglobulin |
US9051375B2 (en) * | 2010-12-21 | 2015-06-09 | The University Of Western Ontario | Alkali-resistant variants of protein A and their use in affinity chromatography |
US9273151B2 (en) | 2011-03-24 | 2016-03-01 | Kaneka Corporation | Proteinaceous-substance-binding low-molecular-weight compound |
US9920112B2 (en) | 2008-08-11 | 2018-03-20 | Emd Millipore Corporation | Immunoglobulin-binding proteins with improved specificity |
US10808013B2 (en) | 2015-01-26 | 2020-10-20 | Kaneka Corporation | Mutant immunoglobulin K chain variable region-binding peptide |
US10844112B2 (en) | 2016-05-09 | 2020-11-24 | Kaneka Corporation | Method for purifying antibody or antibody fragment containing κ-chain variable region |
US10858392B2 (en) | 2015-01-26 | 2020-12-08 | Kaneka Corporation | Affinity separation matrix for purifying protein containing immunoglobulin K chain variable region |
US11208441B2 (en) | 2015-10-22 | 2021-12-28 | Protenova Co., Ltd. | Immunoglobulin-binding polypeptide |
US11753449B2 (en) | 2017-09-25 | 2023-09-12 | Jsr Corporation | Immunoglobulin binding protein, and affinity support using same |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7709209B2 (en) | 2002-03-25 | 2010-05-04 | Ge Healthcare Bio-Sciences Ab | Protein ligands |
SE0200943D0 (en) * | 2002-03-25 | 2002-03-25 | Amersham Biosciences Ab | Mutant protein |
GB0214007D0 (en) * | 2002-06-18 | 2002-07-31 | Common Services Agency | Removal of prion infectivity |
EP1634076A2 (en) * | 2003-06-10 | 2006-03-15 | CatchMabs B.V. | Binding peptides: methods for their generation and use |
SE0301936D0 (en) * | 2003-06-30 | 2003-06-30 | Affibody Ab | New polypeptide |
JP4871126B2 (en) * | 2003-07-04 | 2012-02-08 | アフィボディ・アーベー | Polypeptide having binding affinity for HER2 |
DE05733048T1 (en) | 2004-04-06 | 2007-05-10 | Affibody Ab | SERUMALBUMIN BINDING PEPTIDE CONJUGATES FOR DRUG MANUFACTURING |
CN104710518A (en) * | 2007-07-31 | 2015-06-17 | 阿菲博迪公司 | New albumin binding compositions, methods and uses |
GB2452301A (en) | 2007-08-30 | 2009-03-04 | Ge Healthcare Bio Sciences Ab | Sterilization Method |
EP2339339A4 (en) * | 2008-09-25 | 2016-10-12 | Jsr Corp | Filler for affinity chromatography |
JP5229888B2 (en) * | 2008-09-30 | 2013-07-03 | 独立行政法人産業技術総合研究所 | Protein A mutant protein and antibody capture agent with improved easy dissociation in weakly acidic region |
US9403883B2 (en) | 2009-03-24 | 2016-08-02 | Kaneka Corporation | Protein having affinity for immunoglobulin, and immunoglobulin-binding affinity ligand |
WO2011118699A1 (en) | 2010-03-24 | 2011-09-29 | 株式会社カネカ | Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand |
WO2012133342A1 (en) | 2011-03-25 | 2012-10-04 | 株式会社カネカ | Novel immunoglobulin-binding polypeptide |
WO2014076177A1 (en) * | 2012-11-14 | 2014-05-22 | Affibody Ab | New polypeptide |
WO2014076179A1 (en) | 2012-11-14 | 2014-05-22 | Affibody Ab | New polypeptide |
USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
CN114560906A (en) | 2013-09-04 | 2022-05-31 | Emd密理博公司 | Method for washing affinity chromatographic column based on protein A |
JP6491600B2 (en) | 2013-09-27 | 2019-03-27 | 株式会社カネカ | Method for producing porous cellulose beads using aqueous alkali solution |
EP3079808B1 (en) | 2013-12-12 | 2020-05-27 | EMD Millipore Corporation | Method of separating monomeric protein from protein agregates with a porous membrane comprising a co-polymer of benzyl acrylamide and acrylamide |
JP6369807B2 (en) * | 2014-10-21 | 2018-08-08 | 株式会社プロテイン・エクスプレス | Protein L mutant |
US10723769B2 (en) | 2015-03-26 | 2020-07-28 | Jsr Corporation | Immunoglobulin-binding protein and affinity carrier using same |
US11319359B2 (en) | 2015-04-17 | 2022-05-03 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
WO2017191748A1 (en) * | 2016-05-02 | 2017-11-09 | 株式会社カネカ | Modified immunoglobulin κ chain variable region-binding peptide |
WO2018162501A1 (en) | 2017-03-07 | 2018-09-13 | Jmva Biotech Ab | Modified adsorptive surfaces |
JP7335881B2 (en) | 2018-08-24 | 2023-08-30 | Jsr株式会社 | Immunoglobulin-binding protein and affinity carrier using the same |
WO2022081779A1 (en) | 2020-10-13 | 2022-04-21 | Avitide LLC | Affinity ligand libraries of three-helix bundle proteins and uses thereof |
EP4269590A1 (en) | 2020-12-22 | 2023-11-01 | Protenova Co., Ltd. | Immunoglobulin-binding polypeptide |
JP2024508587A (en) | 2021-02-19 | 2024-02-28 | アヴィタイド エルエルシー | AAV2 affinity agent |
GB2609185A (en) | 2021-05-24 | 2023-02-01 | Astrea Uk Services Ltd | Scaffold for isolation of a biomolecule |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089473A (en) * | 1988-08-29 | 1992-02-18 | Monsanto Company | Somatotropin variants and their use |
US5401832A (en) * | 1984-12-24 | 1995-03-28 | Merck & Co., Inc. | Brain derived and recombinant acidic fibroblast growth factor |
US5580788A (en) * | 1991-07-25 | 1996-12-03 | Oriental Yeast Co., Ltd. | Use of immunoglogulin-binding artificial proteins as molecular weight markers |
US5736499A (en) * | 1995-06-06 | 1998-04-07 | Genencor International, Inc. | Mutant A-amylase |
US5831012A (en) * | 1994-01-14 | 1998-11-03 | Pharmacia & Upjohn Aktiebolag | Bacterial receptor structures |
US6291216B1 (en) * | 1992-04-16 | 2001-09-18 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Affinity supports containing ligands bound to oxirane groups |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8204810L (en) * | 1982-08-23 | 1984-02-24 | Pharmacia Fine Chemicals Ab | HYBRID DNA MOLECULE, TRANSFORMED MICROORGANISM AND PROCEDURE TO MAKE PROTEIN A |
JP2584697B2 (en) * | 1991-08-23 | 1997-02-26 | オリエンタル酵母工業株式会社 | Recombinant protein A for IgG purification |
SE9503925D0 (en) * | 1995-11-07 | 1995-11-07 | Pharmacia Biotech Ab | Separation medium for IgG |
DE69828154T2 (en) * | 1997-03-12 | 2005-06-23 | Smithkline Beecham Corp. | ANTI-ALPHAVBETA3 HUMANIZED MONOCLONAL ANTIBODIES |
-
1998
- 1998-10-21 GB GBGB9823071.7A patent/GB9823071D0/en not_active Ceased
-
1999
- 1999-10-21 US US09/830,080 patent/US6831161B1/en not_active Expired - Lifetime
- 1999-10-21 CA CA2633345A patent/CA2633345C/en not_active Expired - Lifetime
- 1999-10-21 WO PCT/GB1999/003484 patent/WO2000023580A1/en active IP Right Grant
- 1999-10-21 AT AT99950942T patent/ATE305970T1/en not_active IP Right Cessation
- 1999-10-21 CA CA002347960A patent/CA2347960C/en not_active Expired - Lifetime
- 1999-10-21 EP EP99950942A patent/EP1123389B1/en not_active Expired - Lifetime
- 1999-10-21 DK DK99950942T patent/DK1123389T3/en active
- 1999-10-21 EP EP05077192A patent/EP1672068A1/en not_active Ceased
- 1999-10-21 JP JP2000577291A patent/JP4801258B2/en not_active Expired - Lifetime
- 1999-10-21 AU AU63532/99A patent/AU773368B2/en not_active Expired
- 1999-10-21 DE DE69927598T patent/DE69927598T2/en not_active Expired - Lifetime
-
2001
- 2001-04-20 ZA ZA200103252A patent/ZA200103252B/en unknown
- 2001-04-20 NO NO20011969A patent/NO323994B1/en not_active IP Right Cessation
-
2004
- 2004-12-01 US US11/000,747 patent/US20050100970A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5401832A (en) * | 1984-12-24 | 1995-03-28 | Merck & Co., Inc. | Brain derived and recombinant acidic fibroblast growth factor |
US5089473A (en) * | 1988-08-29 | 1992-02-18 | Monsanto Company | Somatotropin variants and their use |
US5580788A (en) * | 1991-07-25 | 1996-12-03 | Oriental Yeast Co., Ltd. | Use of immunoglogulin-binding artificial proteins as molecular weight markers |
US6291216B1 (en) * | 1992-04-16 | 2001-09-18 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Affinity supports containing ligands bound to oxirane groups |
US5831012A (en) * | 1994-01-14 | 1998-11-03 | Pharmacia & Upjohn Aktiebolag | Bacterial receptor structures |
US5736499A (en) * | 1995-06-06 | 1998-04-07 | Genencor International, Inc. | Mutant A-amylase |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008039141A1 (en) * | 2006-09-29 | 2008-04-03 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand comprising domain c from staphyloccocus aureus protein a for antibody isolation |
US9663559B2 (en) | 2006-09-29 | 2017-05-30 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation |
US8329860B2 (en) | 2006-09-29 | 2012-12-11 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation |
US11517879B2 (en) | 2006-09-29 | 2022-12-06 | Cytiva Bioprocess R&D Ab | Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation |
US8772447B2 (en) | 2006-09-29 | 2014-07-08 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand comprising domain C from staphylococcus aureus protein A for antibody isolation |
US10213765B2 (en) | 2006-09-29 | 2019-02-26 | GE Healthcare Bioprocess R&D | Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation |
US10875007B2 (en) | 2006-09-29 | 2020-12-29 | Cytiva Bioprocess R&D Ab | Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation |
US10343142B2 (en) | 2006-09-29 | 2019-07-09 | Ge Healthcare Bioprocess R&D Ab | Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation |
US9920112B2 (en) | 2008-08-11 | 2018-03-20 | Emd Millipore Corporation | Immunoglobulin-binding proteins with improved specificity |
US11084851B2 (en) | 2008-12-24 | 2021-08-10 | Emd Millipore Corporation | Caustic stable chromatography ligands |
US20100221844A1 (en) * | 2008-12-24 | 2010-09-02 | Millipore Corporation | Caustic stable chromatography ligands |
US10072050B2 (en) | 2008-12-24 | 2018-09-11 | Emd Millipore Corporation | Caustic stable chromatography ligands |
US9051375B2 (en) * | 2010-12-21 | 2015-06-09 | The University Of Western Ontario | Alkali-resistant variants of protein A and their use in affinity chromatography |
US9040661B2 (en) | 2010-12-21 | 2015-05-26 | Jsr Corporation | Support for affinity chromatography and method for isolating immunoglobulin |
US9273151B2 (en) | 2011-03-24 | 2016-03-01 | Kaneka Corporation | Proteinaceous-substance-binding low-molecular-weight compound |
US9018305B2 (en) | 2011-06-08 | 2015-04-28 | Emd Millipore Corporation | Chromatography matrices including novel Staphylococcus aureus protein a based ligands |
US9376474B1 (en) | 2011-06-08 | 2016-06-28 | Emd Millipore Corporation | Chromatography matrices including novel Staphylococcus aureus protein a based ligands |
US9234010B2 (en) | 2011-06-08 | 2016-01-12 | Emd Millipore Corporation | Chromatography matrices including novel Staphylococcus aureus protein A based ligands |
US8895706B2 (en) | 2011-06-08 | 2014-11-25 | Emd Millipore Corporation | Chromatography matrices including novel Staphylococcus aureus protein A based ligands |
US8754196B2 (en) | 2011-06-08 | 2014-06-17 | Emd Millipore Corporation | Chromatography matrices including novel Staphylococcus aureus protein A based ligands |
US10808013B2 (en) | 2015-01-26 | 2020-10-20 | Kaneka Corporation | Mutant immunoglobulin K chain variable region-binding peptide |
US10858392B2 (en) | 2015-01-26 | 2020-12-08 | Kaneka Corporation | Affinity separation matrix for purifying protein containing immunoglobulin K chain variable region |
US11208441B2 (en) | 2015-10-22 | 2021-12-28 | Protenova Co., Ltd. | Immunoglobulin-binding polypeptide |
US10844112B2 (en) | 2016-05-09 | 2020-11-24 | Kaneka Corporation | Method for purifying antibody or antibody fragment containing κ-chain variable region |
US11753449B2 (en) | 2017-09-25 | 2023-09-12 | Jsr Corporation | Immunoglobulin binding protein, and affinity support using same |
Also Published As
Publication number | Publication date |
---|---|
DE69927598D1 (en) | 2006-02-16 |
ATE305970T1 (en) | 2005-10-15 |
DK1123389T3 (en) | 2006-01-16 |
JP2002527107A (en) | 2002-08-27 |
JP4801258B2 (en) | 2011-10-26 |
US6831161B1 (en) | 2004-12-14 |
DE69927598T2 (en) | 2006-07-13 |
EP1672068A1 (en) | 2006-06-21 |
AU6353299A (en) | 2000-05-08 |
ZA200103252B (en) | 2002-07-22 |
NO323994B1 (en) | 2007-07-30 |
CA2633345C (en) | 2013-02-26 |
NO20011969D0 (en) | 2001-04-20 |
CA2347960A1 (en) | 2000-04-27 |
CA2633345A1 (en) | 2000-04-27 |
CA2347960C (en) | 2008-08-05 |
AU773368B2 (en) | 2004-05-20 |
EP1123389B1 (en) | 2005-10-05 |
EP1123389A1 (en) | 2001-08-16 |
GB9823071D0 (en) | 1998-12-16 |
NO20011969L (en) | 2001-06-19 |
WO2000023580A1 (en) | 2000-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6831161B1 (en) | Method of affinity separation and ligands for use therein | |
AU2016293063B2 (en) | Novel immunoglobulin-binding proteins and their use in affinity purification | |
O'Neil et al. | Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library | |
EP2690173B1 (en) | Protein for affinity-separation matrix | |
EP0904541B1 (en) | PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (tPA) | |
EP1179014B1 (en) | Derivatives of the z domain from staphylococcal protein a (spa) interacting with at least one domain of human factor viii | |
US6602977B1 (en) | Receptor structures | |
KR20190038560A (en) | Alkali-stable FC-binding protein for affinity chromatography | |
JP5951509B2 (en) | Immunoglobulin GFc region binding polypeptide | |
KR20200116963A (en) | Fc binding protein with cysteine in the C-terminal helical region | |
US20180215785A1 (en) | Method for purifying antibody-like protein | |
CA2399809A1 (en) | Combinatorial protein domains | |
KR20230112616A (en) | Affinity Ligand Library of Triple-Helix Bundle Proteins and Uses Thereof | |
US20180215836A1 (en) | Immunoglobulin-binding modified protein | |
KR20110003547A (en) | Artificial protein scaffolds | |
US20180170973A1 (en) | Immunoglobulin-binding modified protein | |
US20180215795A1 (en) | ANTIBODY-BINDING PROTEIN HAVING REDUCED ANTIBODY-BINDING CAPACITY IN ACIDIC pH REGIONS | |
JP2002058479A (en) | Method for obtaining comformational recognition amino acid sequence | |
US20180215796A1 (en) | ANTIBODY-BINDING PROTEIN HAVING REDUCED ANTIBODY BINDING CAPACITY IN ACIDIC pH REGION | |
EP1674568A1 (en) | Method for screening and selecting ligands | |
Bozovičar et al. | Ligand Selection for Affinity Chromatography Using Phage Display | |
Nygren | Affinity ligands from biological combinatorial libraries |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AFFIBODY BIOTECHNOLOGY AB,SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AFFIBODY AB;REEL/FRAME:018961/0824 Effective date: 20061218 Owner name: AFFIBODY BIOTECHNOLOGY AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AFFIBODY AB;REEL/FRAME:018961/0824 Effective date: 20061218 |
|
AS | Assignment |
Owner name: AFFIBODY AB,SWEDEN Free format text: CHANGE OF NAME;ASSIGNOR:AFFIBODY BIOTECHNOLOGY AB;REEL/FRAME:018989/0492 Effective date: 20070129 Owner name: AFFIBODY AB, SWEDEN Free format text: CHANGE OF NAME;ASSIGNOR:AFFIBODY BIOTECHNOLOGY AB;REEL/FRAME:018989/0492 Effective date: 20070129 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |